William “bill” conkling to assume the role of chief executive officer as of february 1, 2022

Newark, n.j., jan. 21, 2022 (globe newswire) -- rafael holdings, inc., (nyse: rfl), a company focused on discovering and developing novel cancer and immune metabolism therapeuties through its barer institute and investment in rafael pharmaceuticals, inc. and other early-stage ventures, today announced several changes to its leadership team. william (bill) conkling will remain with the company and assume the responsibilities of chief executive officer from ameet mallik as of february 1, 2022.
RFL Ratings Summary
RFL Quant Ranking